Natera (NTRA) Hits 52-Week High Amid Biotech Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 Nov 25
Source: Fool
Shares of Natera (NTRA.O) surged today, reaching a new 52-week high as investor sentiment in the biotech sector remains robust. This breakout signals strong bullish momentum, supported by an average analyst rating of 'Buy' and a mean price target of $235.20. The recent performance of Natera aligns with broader trends in the biotech industry, where several companies, including Olema Pharmaceuticals and Rigel Pharmaceuticals, have also achieved significant stock milestones due to positive trial outcomes. As firms prepare for key regulatory submissions and clinical trials, Natera's growth outlook for 2025 further enhances its appeal to investors, emphasizing the potential for long-term value amidst short-term fluctuations.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 252.88 USD with a low forecast of 172.00 USD and a high forecast of 300.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 235.930
Low
172.00
Averages
252.88
High
300.00
Current: 235.930
Low
172.00
Averages
252.88
High
300.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
